Urovant Sciences announced the first patient has been enrolled in a Phase 2a study evaluating the efficacy and safety of URO-902, a novel gene therapy product ...
After childbirth, the risk for pelvic floor disorders varies by delivery mode, according to a study published in the Dec. 18 issue of the Journal of the American Medical Association.....
Axonics Modulation Technologies has pulled in a meaty IPO as it looks to compete with medical technology major Medtronic for its neuromodulation device in overactive bladder (OAB).